Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine

Published: Tuesday, March 05, 2013
Last Updated: Tuesday, March 05, 2013
Bookmark and Share
Key patent application covers ICT-121, an immunotherapeutic vaccine targeting CD133, an important cancer stem cell marker that is commonly overexpressed on a broad range of solid tumors.

The patent includes claims covering composition of matter as well as methods of use. Specifically, the claims encompass immunogens comprising a CD133 epitope and variants thereof as well as methods of using such immunogens in immunization and to elicit cytotoxic T lymphocyte responses that are specific for tumor cells expressing HLA-A2.

“This issued patent provides significant protection for ICT-121 with what we believe are broad claims, and is an important addition to ImmunoCellular’s intellectual property estate for our cancer vaccines and monoclonal antibodies,” said Andrew Gengos, ImmunoCellular Chief Executive Officer. “We believe that our growing IP asset strengthens our leadership position in the cancer immunotherapy field, and we look forward to continuing to advance our cancer immunotherapy product candidates through the development process.”

ICT-121 is a dendritic cell vaccine. CD133 is highly expressed on cancer stem cells on most solid tumors, including brain, colon, non-small cell lung, melanoma, pancreatic and breast cancers. ImmunoCellular plans to support an investigator-sponsored, 20-patient phase I trial in recurrent glioblastoma at Cedars-Sinai Medical Center.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ImmunoCellular Therapeutics Announces Issuance of Key Patent for Cancer Vaccine Target
The US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13Ra2) in cancer immunotherapy.
Friday, May 17, 2013
ImmunoCellular Therapeutics’ Investigational New Drug Application for ICT-140 Allowed by the FDA
Investigational new drug (IND) application for ICT-140 paves the way for conducting a clinical trial.
Wednesday, January 30, 2013
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
Exposure To Routine Viruses Makes Mice Better Test Subjects
Study shows that infections make mouse immune system act more like that in humans.
Immune Booster Tested in Advanced Merkel Cell Cancer
The immunotherapy drug produced durable responses in many patients.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!